| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | TOP1; DNA topoisomerase 1; DNA topoisomerase I |
| Entrez GeneID | 7150 |
| WB Predicted band size | Calculated MW: 91 kDa; Observed MW: 91 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthesized peptide derived from human TOP1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Topoisomerase I抗体的3篇参考文献(名称、作者及摘要内容概括)：
1. **"Autoantibodies to DNA topoisomerase I in systemic sclerosis: a study of antigen-driven immune response"**
*作者：Kuwana M, et al. (2002)*
**摘要**：研究系统性硬化症患者体内Topoisomerase I抗体的抗原驱动免疫反应，发现抗体反应与特定临床亚型(如弥漫性皮肤硬化症)相关，提示其作为疾病标志物的潜在价值。
2. **"Comparison of a novel ELISA with the immunodiffusion assay for detection of anti-topoisomerase I antibodies"**
*作者：Mahler M, Fritzler MJ (2003)*
**摘要**：开发并验证一种新型ELISA法检测抗Topoisomerase I抗体，与传统免疫扩散法对比，显示更高的敏感性和特异性，支持其在临床诊断中的应用。
3. **"Clinical significance of anti-topoisomerase I antibodies in systemic sclerosis"**
*作者：Steen VD, et al. (2005)*
**摘要**：通过长期随访系统性硬化症患者，发现Topoisomerase I抗体阳性与肺纤维化风险增加及疾病进展加速显著相关，强调其预后价值。
4. **"DNA topoisomerases: structure, function, and mechanism"**
*作者：Champoux JJ (2001)*
**摘要**：综述Topoisomerase I的分子机制及其在DNA复制中的作用，为理解抗体干扰酶功能(如自身免疫疾病中的致病机制)提供理论依据。
(注：以上为简化示例，实际文献需通过PubMed或学术数据库检索确认详细信息。)
Topoisomerase I (Topo I) antibodies are autoantibodies directed against the enzyme Topo I, also known as Scl-70. Topo I plays a critical role in DNA replication and transcription by relieving torsional stress through temporary cleavage and rejoining of DNA strands. These antibodies are primarily associated with systemic sclerosis (SSc), particularly the diffuse cutaneous subtype (dcSSc), and serve as a hallmark serological marker.
First identified in the 1980s, anti-Topo I antibodies are detected in approximately 30-40% of SSc patients, with higher prevalence in dcSSc. Their presence correlates with severe disease manifestations, including pulmonary fibrosis, cardiac involvement, and skin thickening. While highly specific for SSc (95-98%), they are rarely observed in other connective tissue diseases like systemic lupus erythematosus or polymyositis.
Clinically, anti-Topo I antibodies aid in diagnosis, prognosis, and disease monitoring. Their detection typically involves enzyme-linked immunosorbent assay (ELISA) or immunoprecipitation. Patients positive for these antibodies require close surveillance for organ complications. Research also explores their role in pathogenesis, as Topo I overexpression in fibroblasts may trigger autoimmunity and tissue fibrosis. Despite advances, the exact mechanisms linking antibody production to disease progression remain under investigation, highlighting their significance in both clinical and research contexts.
×
